Skip to main content
. 2014 Dec 30;26(3):326–333. doi: 10.1111/nmo.12264

Figure 4.

Figure 4

Percentages of patients with specified increases in weekly CSBM frequency and SBM frequency at week 12 (pooled IBS-C phase 3 ITT population). At week 12, a greater percentage of patients treated with linaclotide met incremental levels of increase in weekly CSBM frequency and SBM frequency compared with placebo patients (p < 0.0001 for linaclotide compared with placebo for each level of improvement using Fisher's exact test for both CSBM and SBM frequency).